Yan Chao team found that cannabinoids can be used to treat gelactoma

Hemphenol (cannabidiol, CBD) is from natural small molecular compounds from marijuana, different THC in cannabis, and CBD does not have neuromic and addictive, human use is very safe, in recent years in a variety of nerves and mental systems Diseases show a good biological effect, which has become a star molecule in the field of neur pharmacology [1, 2]. 2018 US FDA officially approves CBD for treatment difficult children's epilepsy [3], CBD is also in progress, however, CBD potential anti-tumor value research is small.

Recently, Nanjing University School of Life Sciences, Yan Chao, published article "Cannabidiol Inhibits Human Glioma By Induction of Lethal Mitophagy Through Activating Trpv4", starting to use CBD to treat gylastic tumors, and systematically clarify CBD suppression The target and mechanism of cancer effects is expected to rapidly transform to the clinical treatment of gelactoma.

Glioma (or glioma) is the most common type of brain tumor, wherein the highest malignant sub-colloidal squeese is very poor, and the average survival period is only around 14 months. Temozolomide (TMZ) is currently clinically treating the unique first-line chemotherapeutic drugs in glioma, but problems such as drug-resistant and side effects of mromazole have always restricted its role in clinical practice. To date, emerging immunotherapy in gliomas is also finalized in failure.

Surgery: "Sao Hai" kill the glioma
One of the biggest obstacles in glioma drug research and development is the blood-brain barrier. Most clinical effective drugs eventually do not pass this test in the human body. The team is another way to find a lead compound that may inhibit gliomas from the known natural product that can use the natural product of the human blood brain barrier. "In 2012, in the United States, Colorado, in the United States, I was doing the University of Colorado. I was in Colorado. I thought that it was possible to quickly enter the brain. Is it possible to use cannabin to treat gliomas? Until 2016, I returned to China to form a laboratory to have the opportunity to start verifying this idea, "Yan Chao said.

Always remember, there will be reverberations
Sure enough, the team quickly confirmed in animal experiments to inhibit glioma progression. What is even more surprised, when the CBD is in use, the survival period of the tumor mice is more than doubled. "We and the Gulou Hospital neurosurgery cooperation, using glioma patient primary cells have established a large number of mice in situ models, which can observe a significant tumor cancer effect, so we special confidence in this data" Yan Chao said.

Figure 1: Progress in the conformity inhibitory glioma in CBD and tubzoliamide

However, the exploration of the CBD pharmacological mechanism is the truly time consuming process. "Natural products are generally more than 'dirty', often there are many targets, but this does not hinder aspirin and metformin into a generation of gods." Yan Chao said. In order to find the main target of CBD inhibiting glioma, the team traversed all reports or predicted cannabin possible targets, combined with chemical student probes, and finally locks the target in TRPV4 ion channel [5]; next The team's strict pharmacological experiment design demonstrates that the CBD can act as a TRPV4 agonist, causing calcium ion internal flow, resulting in mitochondrial dysfunction, inducing mitochondrial autophagy, and ultimately killing organoma cells.

Figure 2: Molecular mechanism of CBD inhibiting glioma

Transformation prospect: and telromisazole in use treatment glioma
"CBD was approved by FDA in 2018 to treat children's epilepsy, which is the maximum recognition of its safety. Our results suggest that CBD indications may expand to glioma, especially the clinical first-line chemotherapy drug timomamide The combination may have a better effect. We are actively promoting the clinical experiments initiated by researchers; but according to existing regulations, it is possible to choose the drug-label use .The Patient Cannot Wait ! "Talking about the future application prospects, Yan Chao is full of expectations.
Professor Yan Chao, Nanjing University, Associate Professor Liu Xiangyu, a Gulou Hospital, and Professor Hang Chunhua as the commonal information of the paper, and Nanjing college student's Ph.D. Huang Tunfei's first author of the paper.